Hympavzi (Marstacimab-hncq)

Hympavzi (marstacimab-hncq) is a tissue factor pathway inhibitor (TFPI) antagonist used for the prevention or reduction of the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.

Recommended Dosage: The recommended loading dose is 300 mg (two 150 mg SC injections). In case more than one injection is needed to deliver a complete dose, consider different injection sites for administering each injection. After one week of the loading dose, start maintenance dosing of 150 mg administered every week by SC injection on the same day each week, at any time of day.

Adjust the dose to 300 mg SC injection weekly in patients weighing more than or equal to 50 kg when control of bleeding events is judged to be inadequate by the clinician. The safety and efficacy of therapy at doses beyond 300 mg weekly have not been assessed. If more than one injection is needed to deliver a complete dose, consider administering each injection at a different injection site.

• Serious hypersensitivity reactions such as anaphylaxis, may develop with Hympavzi treatment. Symptoms including rash, swelling, or difficulty breathing require prompt medical attention. Stop using the medicine if hypersensitivity occurs, and avoid re-administration in those with previous reactions.
• Treatment with Hympavzi 150 mg/mL may increase the risk of thromboembolic events like deep vein thrombosis or pulmonary embolism. Assess patients closely, mainly those with predisposing conditions. Patients should report symptoms like leg swelling, chest pain, or shortness of breath promptly.
• This therapeutic drug may cause harm to the fetus when used during pregnancy. Women of childbearing age should use promising contraception during treatment and for a certain period afterward. Discuss probable risks with those planning a pregnancy or currently pregnant.
• It is not known if this drug is excreted in human milk or its effects on a nursing infant. Women should not breastfeed during treatment and consult their doctor about all the other alternative feeding options for infant safety.
• Marstacimab-hncq may impair fertility or pose risks during pregnancy. Females should consider contraception throughout the treatment, while males who want to father a child should discuss probable risks with their clinician. Proper counseling is required before initiating therapy.

What documents are required to import HYMPAVZI to India?

HYMPAVZI (marstacimab-hncq) injection can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is HYMPAVZI available in India?

HYMPAVZI (marstacimab-hncq injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Hympavzi in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait,
• Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

HYMPAVZI can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of HYMPAVZI (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Hympavzi 150 mg/mL injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source HYMPAVZI (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Hympavzi®?

Marstacimab-hncq is a Generic Name for the trade name drug Hympavzi®.

What is the manufacturer's name for Hympavzi®?

Hympavzi® is manufactured by Pfizer Inc.

Does the FDA approve Hympavzi®?

Yes, Hympavzi® is approved by the FDA. Date of first approval: October 11, 2024.

What is the dosage and form of Hympavzi® supplied?

Hympavzi is supplied in Injection: 150 mg/mL in a single-dose prefilled syringe and 150 mg/mL in a single-dose prefilled pen for subcutaneous use.

What are the most common side effects of Hympavzi®?

The most common side effects of Hympavzi® are headache, injection site reaction, and pruritus.

How much does Hympavzi® injection cost in India?

Prices of Hympavzi may fluctuate over time due to market dynamics and regulatory changes. To get the most recent details on Hympavzi injection cost in India, please Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Hympavzi® be available in SAARC countries?

Apart from Gulf countries, Hympavzi® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Hympavzi® injections in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Hympavzi® injections online in India?

Yes, one can buy Hympavzi 150 mg/mL online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can facilitate the supply of Hympavzi® injections through legal channels.

What are the storage conditions of Hympavzi® 150 mg/mL injections?

Store refrigerated at 36-46°F (2-8°C) in the original carton to protect from light. It is not advisable to freeze or shake it.